Results 11 to 20 of about 106,545 (283)
Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels [PDF]
Blood, 2003 Corbin and colleagues analyze in their report[1][1] the biochemical and biologic effects of several mutations in the kinase domain of the Bcr-Abl protein identified in patients who developed resistance to imatinib.
Carlo Gambacorti‐Passerini +2 more
openalex +4 more sources
SRCircumventing imatinib resistance [PDF]
Cancer Cell, 2004 The ABL inhibitor imatinib is a highly effective therapy for patients with chronic myeloid leukemia. Relapses after an initial response have been observed in some patients, and mutations of the BCR-ABL gene are the most common mechanism driving these relapses.
Brian J. Druker +2 more
openaire +2 more sources
Exploiting the promiscuity of imatinib [PDF]
Journal of Biology, 2009 The protein kinase inhibitor imatinib, also known as Gleevec, has been a notable success in treating chronic myelogenous leukemia. A recent paper in BMC Structural Biology reports a 1.75 A crystal structure of imatinib bound to the oxidoreductase NQO2 and reveals insights into the binding specificity and the off-target effects of the inhibitor.
Lee, Shun J, Wang, Jean YJ
openaire +5 more sources
The Oncologist, 2007 Learning Objectives After completing this course, the reader will be able to: Identify the current indications for imatinib.Describe the pharmacokinetics of imatinib.Discuss the mechanisms involved in imatinib resistance. Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist ...
Christine E, de Kogel +1 more
openaire +2 more sources
Imatinib mesylate in chordoma [PDF]
Cancer, 2004 AbstractBACKGROUNDTo the authors' knowledge, no effective medical therapy currently is available for advanced chordoma. Imatinib mesylate is a tyrosine kinase inhibitor targeting platelet‐derived growth factor receptor‐β (PDGFRB), BCR‐ABL, and KIT.METHODSSix patients with advanced chordoma were treated with imatinib mesylate at a dose of 800 mg daily ...
Casali, Paolo G. +17 more
openaire +3 more sources
A rare case of melanosis of the hard palate mucosa in a patient with chronic myeloid leukemia [PDF]
, 2015 Imatinib Mesylate, also known as Gleevec or ST1-571, is a tyrosine-kinase inhibitor used as the gold standard medication for the chronic myeloid leukemia (CML); Imatinib has indeed deeply revolutionized the CML therapy allowing most patients to have a ...
Bosco, Daniela +4 more
core +3 more sources
Journal of Medical Case Reports, 2011 Introduction Adjuvant imatinib improves recurrence-free survival of patients following resection of primary KIT-positive gastrointestinal stromal tumors.
Kang Yoon-Koo
doaj +1 more source
Lack of Association between C1236T, G2677T/A and C3435T Variants of the ABCB1 Gene and Imatinib Response in Iranian Chronic Myeloid Leukemia Patients [PDF]
Journal of Sciences, Islamic Republic of Iran, 2021 Imatinib introduction caused to improve the clinical outcomes of chronic myeloid leukemia (CML) patients. Despite the significant effects of Imatinib, pharmacogenetic variables induced treatment resistant is also observed.
Maedeh Khosravi +7 more
doaj +1 more source
Frontiers in Systems Neuroscience, 2022 Lamina propria interstitial cells that express the tyrosine kinase receptor, platelet-derived growth factor receptor alpha (PDGFRα) may play a role in urinary sensory signaling.
Megan E. Perkins +3 more
doaj +1 more source
Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia [PDF]
, 2017 Since the advent of tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib, and dasatinib, chronic myelogenous leukemia (CML) prognosis has improved greatly. However, ~30-40% of patients develop resistance to imatinib therapy.
Bandyopadhyay, Shovik +6 more
core +3 more sources